Safety data in randomised real-world evidence studies: Salford Lung Study learnings
Open Access
- 11 March 2021
- journal article
- review article
- Published by European Respiratory Society (ERS) in ERJ Open Research
Abstract
Evidence to support clinical decision making must be based on safety data that have been captured, analysed, and interpreted in a robust and reliable way. Randomised real-world evidence (RRWE) studies provide the opportunity to evaluate the use of medicines in patients and settings representative of routine clinical practice. However, elements that underpin the design of RRWE studies can have a significant impact upon the analysis, interpretation, and implications of safety data. In this narrative review, we use data from the Salford Lung Study; two prospective, 12-month, open-label, parallel-group, phase III randomised controlled trials conducted in primary care in the UK; to highlight the importance of capturing treatment modifications when attempting to evaluate safety events according to actual treatment exposure. We demonstrate that analysing safety data by actual treatment received (i.e. accounting for the treatment modifications that occur routinely in the primary care setting) provides additional insight beyond analysing according to randomised treatment strategy only. It is therefore proposed that understanding of safety data from RRWE trials can be optimised by analysing both by randomised group and by actual treatment received.Keywords
Funding Information
- GlaxoSmithKline
This publication has 13 references indexed in Scilit:
- Effectiveness versus efficacy trials in COPD: how study design influences outcomes and applicabilityEuropean Respiratory Journal, 2018
- Putting patients in control of data from electronic health recordsBMJ, 2018
- Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trialThe Lancet, 2017
- Monitoring safety in a phase III real-world effectiveness trial: use of novel methodology in the Salford Lung StudyPharmacoepidemiology and Drug Safety, 2016
- Effectiveness of Fluticasone Furoate–Vilanterol for COPD in Clinical PracticeThe New England Journal of Medicine, 2016
- The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in asthmaBMC Pulmonary Medicine, 2015
- The Salford Lung Study protocol: a pragmatic, randomised phase III real-world effectiveness trial in chronic obstructive pulmonary disease.Respiratory Research, 2015
- Obtaining real-world evidence: the Salford Lung StudyThorax, 2014
- The role for pragmatic randomized controlled trials (pRCTs) in comparative effectiveness researchClinical Trials, 2012
- How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease?Respiratory Medicine, 2005